camrelizumab + oxaliplatin + tegafur + capecitabine

This is a combination therapy consisting of four agents: - **Camrelizumab** is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance T-cell mediated antitumor responses. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. - **Tegafur** is an oral prodrug of 5-fluorouracil (5-FU), which inhibits thymidylate synthase, disrupting DNA synthesis in cancer cells. - **Capecitabine** is another oral prodrug of 5-FU, also inhibiting thymidylate synthase. This combination leverages both immunotherapy and chemotherapy mechanisms. Camrelizumab enhances immune-mediated tumor destruction, while oxaliplatin, tegafur, and capecitabine provide cytotoxic effects through DNA damage and inhibition of nucleotide synthesis. Such regimens are being explored for the treatment of various solid tumors including gastric cancer, gastroesophageal junction cancer, colorectal cancer, and others[1][2][7].